Nancy Lurker - Dec 28, 2023 Form 4/A Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Executive Vice Chair, Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Dec 28, 2023
Transactions value $
$0
Form type
4/A
Date filed
1/3/2024, 06:37 PM
Date Of Original Report
Jan 2, 2024
Previous filing
Dec 6, 2023
Next filing
Jan 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Gift $0 -52.2K -30.61% $0.00 118K Dec 28, 2023 Direct F1, F2
transaction EYPT Common Stock Gift $0 +52.2K $0.00 52.2K Dec 28, 2023 By Family Trust F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Gift $0 -31.2K -33.33% $0.00 62.3K Dec 28, 2023 Common Stock 31.2K $13.13 Direct F4, F5
transaction EYPT Stock Option (Right to Buy) Gift $0 +31.2K +25.93% $0.00 151K Dec 28, 2023 Common Stock 31.2K $13.13 By Family Trust F3, F4, F5
transaction EYPT Stock Option (Right to Buy) Gift $0 -10.9K -70% $0.00 4.67K Dec 28, 2023 Common Stock 10.9K $12.90 Direct F6, F7
transaction EYPT Stock Option (Right to Buy) Gift $0 +10.9K +18.42% $0.00 70.1K Dec 28, 2023 Common Stock 10.9K $12.90 By Family Trust F3, F6, F7
transaction EYPT Stock Option (Right to Buy) Gift $0 -35K -21.21% $0.00 130K Dec 28, 2023 Common Stock 35K $10.13 Direct F8, F9
transaction EYPT Stock Option (Right to Buy) Gift $0 +35K +46.67% $0.00 110K Dec 28, 2023 Common Stock 35K $10.13 By Family Trust F3, F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was inadvertently left off of the original Form 4 filing on January 2, 2024.
F2 On December 28, 2023, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust.
F3 These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4 On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 151,370 shares of Common Stock of the Company, of which 120,206 had been previously gifted on May 11, 2023.
F5 The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.
F6 On December 28, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 71,684 shares of Common Stock of the Company, of which 59,220 had been previously gifted on May 11, 2023.
F7 The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024.
F8 On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 110,000 shares of Common Stock of the Company, of which 75,000 had been previously gifted on May 11, 2023.
F9 The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.